Teva to divest $1B in assets to clear antitrust hurdles to Allergan deal: Reuters

Carly Helfand Back in July, Teva agreed to pick up Allergan's generics business for $ 40.5 billion. To get that deal past regulators, though, it's going to have to divest some ...

Allergan CEO Saunders could cash out Pfizer deal with $187M, Bloomberg figures

Eric Palmer Even if Brent Saunders does not get the CEO role at Pfizer as a condition of Allergan agreeing to a buyout, which is reportedly being demanded, he will still get ...

Zoetis agrees on $765M deal for aquaculture leader Pharmaq

Carly Helfand Animal health leader Zoetis–which has been the subject of many a pharma buyout rumor–is making a pickup of its own. Late Monday, the Pfizer spinoff announced ...

‘Pfizergan’ deal talks draw tax inversion opposition from Clinton, Trump

Carly Helfand Pfizer and Allergan–which both confirmed on Thursday that they're in "friendly" deal talks–may be intrigued with the prospect of a tie-up. But ...

Grifols bags €100M for Alzheimer’s R&D; Ipsen inks $137M cancer deal; Oryzon raises €17M

Nick Paul Taylor In this week's EuroBiotech Report, Catalan biotech Grifols secured a €100 million ($ 110 million) loan from the European Investment Bank's €315 billion ...

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Eric Palmer Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($ 78.1 million) plant to produce its FlexPen prefilled devices to better ...

Just wait, Perrigo investor urges. We can get the same return–without a Mylan deal

Carly Helfand All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli ...

India’s Cipla gets U.S. beachhead with $550M deal for 2 generics operations

Eric Palmer India's Cipla has lagged behind its compatriots in challenging U.S. drugmakers on their own turf, currently getting less than 10% of its revenues from the lucrative ...

GSK inks exclusive vaccines deal with new GlycoVaxyn affiliate

Amirah Al Idrus When GlaxoSmithKline bought out GlycoVaxyn for $ 190 million earlier this year, it gained a set of early-stage vaccines and commissioned GlycoVaxyn's team ...

Valeant doubles size of its HQ as deal spree continues

Carly Helfand Serial buyer Valeant is expanding quickly, and to keep up, it's expanding its office space, too. The Canadian pharma has leased another 310,000 square feet at Somerset ...

After partnering with Big Pharmas, Incyte bags its own PD-1 drug in $795M deal

John Carroll After signing up for combo studies with all the leaders in the checkpoint inhibitor race, Incyte has found a checkpoint program for itself. FierceBiotech News

Raptor buys into cystic fibrosis with a $418M deal

Damian Garde Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $ 418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis. FierceBiotech ...
Page 2 of 1612345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS